Kymera Therapeutics, Inc. (KYMR) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Watertown, MA, United States. Le PDG actuel est Nello Mainolfi.
KYMR a date d'introduction en bourse 2020-08-21, 208 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $7.34B.
Kymera Therapeutics, Inc. is a biopharmaceutical company founded in 2015 and based in Watertown, Massachusetts that specializes in discovering and developing small molecule therapeutics designed to selectively degrade disease-causing proteins using the body's natural protein degradation system. The company's pipeline includes the IRAK4 program currently in Phase I clinical trials for immunology and inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; the IRAKIMiD program targeting MYD88-mutated diffuse large B cell lymphoma; the STAT3 program for treating hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis; and the MDM2 program for hematological and solid tumors. Through its proprietary protein degradation platform, Kymera aims to address significant unmet medical needs across oncology, immunology, and other therapeutic areas.
